Louisiana State Employees Retirement System Invests $431,000 in Charles River Laboratories International, Inc. $CRL

Louisiana State Employees Retirement System bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,500 shares of the medical research company’s stock, valued at approximately $431,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Tema Etfs LLC purchased a new stake in Charles River Laboratories International during the fourth quarter worth about $26,000. Los Angeles Capital Management LLC purchased a new position in Charles River Laboratories International in the fourth quarter valued at about $42,000. Sfam LLC purchased a new stake in shares of Charles River Laboratories International during the 4th quarter worth approximately $43,000. Activest Wealth Management raised its holdings in shares of Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after purchasing an additional 218 shares during the period. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after purchasing an additional 145 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on CRL. CLSA raised Charles River Laboratories International from a “hold” rating to an “outperform” rating and increased their price objective for the company from $167.00 to $219.00 in a report on Friday, May 29th. Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a research note on Friday, May 8th. Barclays upped their price target on Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Mizuho set a $192.00 price objective on Charles River Laboratories International in a report on Friday, May 8th. Finally, Royal Bank Of Canada began coverage on Charles River Laboratories International in a report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price objective for the company. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average price target of $215.88.

Insider Transactions at Charles River Laboratories International

In other news, Director James C. Foster sold 75,000 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the transaction, the director directly owned 31,596 shares in the company, valued at approximately $7,109,100. This represents a 70.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $224.07 on Thursday. Charles River Laboratories International, Inc. has a fifty-two week low of $144.26 and a fifty-two week high of $236.62. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The stock has a market cap of $10.79 billion, a P/E ratio of -59.59, a price-to-earnings-growth ratio of 2.61 and a beta of 1.40. The firm’s fifty day moving average price is $185.01 and its 200-day moving average price is $185.28.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.10. The company had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.